Semaglutide was associated with improved maximum walking distance across type 2 diabetes subgroups among patients with ...

Semaglutide 1 mg improves walking distance in patients with early peripheral artery disease and type 2 diabetes, regardless ...

New guidelines from the American College of Cardiology and American Heart Association update best practices for managing peripheral artery disease (PAD). The comprehensive clinical guidelines synopsis ...

A burning sensation in the feet is usually harmless and temporary; however if it is chronic it can be due to various ...

According to the National Heart, Lung, and Blood Institute, nearly 10 million people aged 40 and older have Peripheral Artery ...

A post-hoc analysis of STRIDE confirms the benefit of GLP-1 RA in patients with peripheral arterial disease and type 2 ...

Regular walking emerges as a potent strategy against dementia and heart disease, especially for older adults in India, where ...

Global Peripheral Artery Disease Market is valued at approximately USD 4.5 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.7% over the forecast period 2024-2032.

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

This week on Tech Byte we travel to the Vascular Institute of Chattanooga for Dr. Will Harris to show us a new tech they have to help treat Peripheral Arterial Disease (PAD) that is new to this end of ...